ETCTN Phase I/II study of the MEK inhibitor Selumetinib plus DS-8201a (trastuzumab deruxtecan) in KRAS-mutant, HER2-expressing pancreatic ductal adenocarcinoma Adult CIRB - Early Phase Emphasis Active Available to Open